MAP2K7 and familial pancreatic carcinoma: Furthermore, resveratrol, which simultaneously inhibits the activation of PI3K/AKT and MEK/ERK pathways (resulting in activation of FOXO), could be an attractive candidate for the management of pancreatic cancer.